Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 35
Summary
- Conditions
- Sickle Cell Disease
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 2 years and 20 years
- Gender
- Both males and females
Description
The purpose of this study is to investigate host myeloimmunosuppressive conditioning followed by familial haploidentical T cell depleted allogeneic stem cell transplantation in patients with high risk Sickle Cell Disease (SCD). It is hypothesized that it will be safe and well tolerated, and result i...
The purpose of this study is to investigate host myeloimmunosuppressive conditioning followed by familial haploidentical T cell depleted allogeneic stem cell transplantation in patients with high risk Sickle Cell Disease (SCD). It is hypothesized that it will be safe and well tolerated, and result in sustained donor chimerism, acceptable engraftment and immune reconstitution. Also, that it will limit SCD related organ damage resulting in improved and/or stable neurological, neurocognitive, pulmonary and pulmonary vascular function and health related quality of life (QOL). Patients 2-20.99 years of age with a diagnosis of high-risk SCD and with an unaffected HLA partially matched family donor and meeting eligibility criteria (inclusion and exclusion criteria) are eligible.
Tracking Information
- NCT #
- NCT01461837
- Collaborators
- UCSF Benioff Children's Hospital Oakland
- Medical College of Wisconsin
- Washington University School of Medicine
- Tufts Medical Center
- University of California, San Francisco
- University of California, Los Angeles
- Miltenyi Biomedicine GmbH
- Ann & Robert H Lurie Children's Hospital of Chicago
- Investigators
- Principal Investigator: Mitchell S Cairo, MD New York Medical College